The ADC m276-SL-PBD, targeting B7-H3, extended event-free survival (EFS), reduced tumor volume in NB xenograft models, and showed low toxicity, confirming its tolerability and potency (28) (Table 1). This evidence concerns the gene CD276 and neoplasm.